Katherine E. Pinnick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Katherine E. Pinnick has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Fredrik Karpe
Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K.
15 shared publications - Leanne Hodson
Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
7 shared publications Marijana Todorčević
Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Churchill Hospital, Headington, UK
6 shared publications- Matt J. Neville
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
6 shared publications Anne Clark
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford OX3 7LJ, UK
3 shared publicationsClaudia Langenberg
MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK
3 shared publications
Latest Publications
- 31 May 2025
- Published by Springer Nature
- Vol. 2938, 31-46
Adipogenic Differentiation Assay for the Study of Insulin Signaling
In vitro models of adipogenesis are valuable tools for the study of human adipocyte development and function. Prevailing methods rely on the extended use of supraphysiological concentrations of glucose and adipogenic hormones, which can negatively impact some aspects of adipocyte function, in particular, insulin signaling. In this chapter, we present a modified adipogenic differentiation protocol which has been optimized for the study of insulin signaling and glucose uptake in human adipose-derived stem cells (hADSCs).
- 31 May 2025
- Published by Springer Nature
- Vol. 2938, 31-46
Adipogenic Differentiation Assay for the Study of Insulin Signaling
In vitro models of adipogenesis are valuable tools for the study of human adipocyte development and function. Prevailing methods rely on the extended use of supraphysiological concentrations of glucose and adipogenic hormones, which can negatively impact some aspects of adipocyte function, in particular, insulin signaling. In this chapter, we present a modified adipogenic differentiation protocol which has been optimized for the study of insulin signaling and glucose uptake in human adipose-derived stem cells (hADSCs).
- Open Access
- 27 March 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 223, 116171
The value of neck adipose tissue as a predictor for metabolic risk in health and type 2 diabetes
- 27 March 2024
- Published by Elsevier in Biochemical Pharmacology
- Vol. 223, 116171
Open AccessThe value of neck adipose tissue as a predictor for metabolic risk in health and type 2 diabetes
- Open Access
- 27 February 2023
- Published by Taylor & Francis in Adipocyte
- Vol. 12 (1) , 2179339
An optimised protocol for the investigation of insulin signalling in a human cell culture model of adipogenesis
While there is no standardised protocol for the differentiation of human adipocytes in culture, common themes exist in the use of supra-physiological glucose and hormone concentrations, and an absence of exogenous fatty acids. These factors can have detrimental effects on some aspects of adipogenesis and adipocyte function. Here, we present methods for modifying the adipogenic differentiation protocol to overcome impaired glucose uptake and insulin signalling in human adipose-derived stem cell lines derived from the stromovascular fraction of abdominal and gluteal subcutaneous adipose tissue. By reducing the length of exposure to adipogenic hormones, in combination with a physiological glucose concentration (5 mM), and the provision of exogenous fatty acids (reflecting typical dietary fatty acids), we were able to restore early insulin signalling events and glucose uptake, which were impaired by extended use of hormones and a high glucose concentration, respectively. Furthermore, the addition of exogenous fatty acids greatly increased the storage of triglycerides and removed the artificial demand to synthesise all fatty acids by de novo lipogenesis. Thus, modifying the adipogenic cocktail can enhance functional aspects of human adipocytes in vitro and is an important variable to consider prior to in vitro investigations into adipocyte biology.
- 27 February 2023
- Published by Taylor & Francis in Adipocyte
- Vol. 12 (1) , 2179339
Open AccessAn optimised protocol for the investigation of insulin signalling in a human cell culture model of adipogenesis
While there is no standardised protocol for the differentiation of human adipocytes in culture, common themes exist in the use of supra-physiological glucose and hormone concentrations, and an absence of exogenous fatty acids. These factors can have detrimental effects on some aspects of adipogenesis and adipocyte function. Here, we present methods for modifying the adipogenic differentiation protocol to overcome impaired glucose uptake and insulin signalling in human adipose-derived stem cell lines derived from the stromovascular fraction of abdominal and gluteal subcutaneous adipose tissue. By reducing the length of exposure to adipogenic hormones, in combination with a physiological glucose concentration (5 mM), and the provision of exogenous fatty acids (reflecting typical dietary fatty acids), we were able to restore early insulin signalling events and glucose uptake, which were impaired by extended use of hormones and a high glucose concentration, respectively. Furthermore, the addition of exogenous fatty acids greatly increased the storage of triglycerides and removed the artificial demand to synthesise all fatty acids by de novo lipogenesis. Thus, modifying the adipogenic cocktail can enhance functional aspects of human adipocytes in vitro and is an important variable to consider prior to in vitro investigations into adipocyte biology.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Circulating levels of adipose-derived lipokines correlate positively with fasting insulin in states of increased insulin insensitivity in humans
Introduction: Palmitoleate, a proposed adipose tissue (AT)-derived lipokine, has been suggested to contribute to glucose homeostasis. However, data relating to the association between circulating palmitoleate and markers of insulin sensitivity in humans are equivocal. Recently, AT-derived fatty acid-hydroxy fatty acids (FAHFAs) have also been suggested to play a role in glucose homeostasis by increasing glucose uptake in AT. Again, data is conflicting for the association between circulating FAHFAs and markers of insulin sensitivity. The aim of the current work was to clarify the relationships between circulating lipokine concentrations and markers of insulin resistance, using a large cohort of individuals, across a spectrum of adiposity. Methods: Fasting plasma samples (102 female and 77 male) from healthy, well-phenotyped and non-diabetic participants were stratified, based on the 75th centile of fasting plasma insulin concentrations, as normoinsuliaemic (NI) (n=133) or hyperinsulinaemic (HI) (n=45). Circulating concentrations of plasma palmitoleate were measured using gas chromatography and two FAHFA sub-families (PAHSAs and PAHPAs) were measured by liquid chromatography-mass spectrometry. Results: We observed female sex-specific, positive correlations (P<0.05) between fasting insulin and PAHSAs and PAHPAs in the HI group only. In both sexes, similar, but non-significant, trends were also observed between circulating palmitoleate concentration and fasting insulin in the HI group, with no trends in the NI group. The HI group had higher relative fat mass, fasting glucose, plasma PAHSA and PAHPA but there were no differences in age, plasma total NEFA or palmitoleate. Conclusion: Our data suggest that systemic concentrations of palmitoleate may be upregulated in response to insulin insensitivity and, although the same may true of PAHSAs and PAHPAs in females, there is a sexual dimorphic response. However, the usefulness of these lipokines as markers of insulin sensitivity is likely limited as plasma concentrations do not discriminate between individuals classed as NI and HI.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Circulating levels of adipose-derived lipokines correlate positively with fasting insulin in states of increased insulin insensitivity in humans
Introduction: Palmitoleate, a proposed adipose tissue (AT)-derived lipokine, has been suggested to contribute to glucose homeostasis. However, data relating to the association between circulating palmitoleate and markers of insulin sensitivity in humans are equivocal. Recently, AT-derived fatty acid-hydroxy fatty acids (FAHFAs) have also been suggested to play a role in glucose homeostasis by increasing glucose uptake in AT. Again, data is conflicting for the association between circulating FAHFAs and markers of insulin sensitivity. The aim of the current work was to clarify the relationships between circulating lipokine concentrations and markers of insulin resistance, using a large cohort of individuals, across a spectrum of adiposity. Methods: Fasting plasma samples (102 female and 77 male) from healthy, well-phenotyped and non-diabetic participants were stratified, based on the 75th centile of fasting plasma insulin concentrations, as normoinsuliaemic (NI) (n=133) or hyperinsulinaemic (HI) (n=45). Circulating concentrations of plasma palmitoleate were measured using gas chromatography and two FAHFA sub-families (PAHSAs and PAHPAs) were measured by liquid chromatography-mass spectrometry. Results: We observed female sex-specific, positive correlations (P<0.05) between fasting insulin and PAHSAs and PAHPAs in the HI group only. In both sexes, similar, but non-significant, trends were also observed between circulating palmitoleate concentration and fasting insulin in the HI group, with no trends in the NI group. The HI group had higher relative fat mass, fasting glucose, plasma PAHSA and PAHPA but there were no differences in age, plasma total NEFA or palmitoleate. Conclusion: Our data suggest that systemic concentrations of palmitoleate may be upregulated in response to insulin insensitivity and, although the same may true of PAHSAs and PAHPAs in females, there is a sexual dimorphic response. However, the usefulness of these lipokines as markers of insulin sensitivity is likely limited as plasma concentrations do not discriminate between individuals classed as NI and HI.
- Open Access
- 28 July 2022
- Published by Elsevier in Cell Reports
- Vol. 40 (4) , 111136
HOTAIR interacts with PRC2 complex regulating the regional preadipocyte transcriptome and human fat distribution
- 28 July 2022
- Published by Elsevier in Cell Reports
- Vol. 40 (4) , 111136
Open AccessHOTAIR interacts with PRC2 complex regulating the regional preadipocyte transcriptome and human fat distribution
- Open Access
- 3 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
RSPO3 impacts body fat distribution and regulates adipose cell biology in vitro
Fat distribution is an independent cardiometabolic risk factor. However, its molecular and cellular underpinnings remain obscure. Here we demonstrate that two independent GWAS signals at RSPO3, which are associated with increased body mass index-adjusted waist-to-hip ratio, act to specifically increase RSPO3 expression in subcutaneous adipocytes. These variants are also associated with reduced lower-body fat, enlarged gluteal adipocytes and insulin resistance. Based on human cellular studies RSPO3 may limit gluteofemoral adipose tissue (AT) expansion by suppressing adipogenesis and increasing gluteal adipocyte susceptibility to apoptosis. RSPO3 may also promote upper-body fat distribution by stimulating abdominal adipose progenitor (AP) proliferation. The distinct biological responses elicited by RSPO3 in abdominal versus gluteal APs in vitro are associated with differential changes in WNT signalling. Zebrafish carrying a nonsense rspo3 mutation display altered fat distribution. Our study identifies RSPO3 as an important determinant of peripheral AT storage capacity.
- 3 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
Open AccessRSPO3 impacts body fat distribution and regulates adipose cell biology in vitro
Fat distribution is an independent cardiometabolic risk factor. However, its molecular and cellular underpinnings remain obscure. Here we demonstrate that two independent GWAS signals at RSPO3, which are associated with increased body mass index-adjusted waist-to-hip ratio, act to specifically increase RSPO3 expression in subcutaneous adipocytes. These variants are also associated with reduced lower-body fat, enlarged gluteal adipocytes and insulin resistance. Based on human cellular studies RSPO3 may limit gluteofemoral adipose tissue (AT) expansion by suppressing adipogenesis and increasing gluteal adipocyte susceptibility to apoptosis. RSPO3 may also promote upper-body fat distribution by stimulating abdominal adipose progenitor (AP) proliferation. The distinct biological responses elicited by RSPO3 in abdominal versus gluteal APs in vitro are associated with differential changes in WNT signalling. Zebrafish carrying a nonsense rspo3 mutation display altered fat distribution. Our study identifies RSPO3 as an important determinant of peripheral AT storage capacity.
- Open Access
- 22 October 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 43 (12) , 2593
Correction to: Bone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis
We erroneously published the original Article with an incorrect Copyright line. This has been updated in the XML, PDF and HTML versions of this Article.
- 22 October 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 43 (12) , 2593
Open AccessCorrection to: Bone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis
We erroneously published the original Article with an incorrect Copyright line. This has been updated in the XML, PDF and HTML versions of this Article.
- Open Access
- 19 July 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 43 (12) , 2458-2468
Bone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis
Background Bone morphogenetic proteins (BMPs) regulate adipogenesis but it is not clear whether they influence regional adipose tissue (AT) development in humans. Objective To characterise BMP2 expression, BMP2-SMAD1/5/8 signalling, and BMP2′s potential effect on proliferation and adipogenesis in human subcutaneous abdominal and gluteal AT and its constituent preadipocytes. Methods BMP2 expression was measured in whole AT and immortalised preadipocytes via qPCR and Western blot; secreted/circulating BMP2 was measured by ELISA. The effect of BMP2 on preadipocyte proliferation was evaluated using a fluorescent assay. BMP2′s effect on adipogenesis in immortalised preadipocytes was determined via qPCR of adipogenic markers and cellular triacylglycerol (TAG) accumulation. BMP2-SMAD1/5/8 signalling was assessed in immortalised preadipocytes via Western blot and qPCR of ID1 expression. Results BMP2 was expressed and released by abdominal and gluteal AT and preadipocytes. Exogenous BMP2 dose dependently promoted adipogenesis in abdominal preadipocytes only; 50 ng/ml BMP2 increased PPARG2 expression (10-fold compared to vehicle, p < 0.001) and TAG accumulation (3-fold compared to vehicle; p < 0.001). BMP2 stimulated SMAD1/5/8 phosphorylation and ID1 expression in abdominal and gluteal preadipocytes but this was blocked by 500 nM K02288, a type 1 BMP receptor inhibitor (p < 0.001). Co-administration of 500 nM K02288 also inhibited the pro-adipogenic effect of 50 ng/ml BMP2 in abdominal cells; >90% inhibition of TAG accumulation (p < 0.001) and ~50% inhibition of PPARG2 expression (p < 0.001). The endogenous iron regulator erythroferrone reduced BMP2-SMAD1/5/8 signalling by ~30% specifically in subcutaneous abdominal preadipocytes (p < 0.01), suggesting it plays a role in restricting the expansion of the body’s largest AT depot during energy deficiency. Additionally, a waist-hip ratio-increasing common polymorphism near BMP2 is an eQTL associated with ~15% lower BMP2 expression in abdominal and gluteal AT (p < 0.05) as well as altered adipocyte size in male abdominal AT (p < 0.05). Conclusions These data implicate BMP2-SMAD1/5/8 signalling in depot-specific preadipocyte development and abdominal AT expansion in humans.
- 19 July 2019
- Published by Springer Nature in International Journal of Obesity
- Vol. 43 (12) , 2458-2468
Open AccessBone morphogenetic protein 2 is a depot-specific regulator of human adipogenesis
Background Bone morphogenetic proteins (BMPs) regulate adipogenesis but it is not clear whether they influence regional adipose tissue (AT) development in humans. Objective To characterise BMP2 expression, BMP2-SMAD1/5/8 signalling, and BMP2′s potential effect on proliferation and adipogenesis in human subcutaneous abdominal and gluteal AT and its constituent preadipocytes. Methods BMP2 expression was measured in whole AT and immortalised preadipocytes via qPCR and Western blot; secreted/circulating BMP2 was measured by ELISA. The effect of BMP2 on preadipocyte proliferation was evaluated using a fluorescent assay. BMP2′s effect on adipogenesis in immortalised preadipocytes was determined via qPCR of adipogenic markers and cellular triacylglycerol (TAG) accumulation. BMP2-SMAD1/5/8 signalling was assessed in immortalised preadipocytes via Western blot and qPCR of ID1 expression. Results BMP2 was expressed and released by abdominal and gluteal AT and preadipocytes. Exogenous BMP2 dose dependently promoted adipogenesis in abdominal preadipocytes only; 50 ng/ml BMP2 increased PPARG2 expression (10-fold compared to vehicle, p < 0.001) and TAG accumulation (3-fold compared to vehicle; p < 0.001). BMP2 stimulated SMAD1/5/8 phosphorylation and ID1 expression in abdominal and gluteal preadipocytes but this was blocked by 500 nM K02288, a type 1 BMP receptor inhibitor (p < 0.001). Co-administration of 500 nM K02288 also inhibited the pro-adipogenic effect of 50 ng/ml BMP2 in abdominal cells; >90% inhibition of TAG accumulation (p < 0.001) and ~50% inhibition of PPARG2 expression (p < 0.001). The endogenous iron regulator erythroferrone reduced BMP2-SMAD1/5/8 signalling by ~30% specifically in subcutaneous abdominal preadipocytes (p < 0.01), suggesting it plays a role in restricting the expansion of the body’s largest AT depot during energy deficiency. Additionally, a waist-hip ratio-increasing common polymorphism near BMP2 is an eQTL associated with ~15% lower BMP2 expression in abdominal and gluteal AT (p < 0.05) as well as altered adipocyte size in male abdominal AT (p < 0.05). Conclusions These data implicate BMP2-SMAD1/5/8 signalling in depot-specific preadipocyte development and abdominal AT expansion in humans.
- Open Access
- 30 May 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0217644
Regional fat depot masses are influenced by protein-coding gene variants
Waist-to-hip ratio (WHR) is a prominent cardiometabolic risk factor that increases cardio-metabolic disease risk independently of BMI and for which multiple genetic loci have been identified. However, WHR is a relatively crude proxy for fat distribution and it does not capture all variation in fat distribution. We here present a study of the role of coding genetic variants on fat mass in 6 distinct regions of the body, based on dual-energy X-ray absorptiometry imaging on more than 17k participants. We find that the missense variant CCDC92S70C, previously associated with WHR, is associated specifically increased leg fat mass and reduced visceral but not subcutaneous central fat. The minor allele-carrying transcript of CCDC92 is constitutively more highly expressed in adipose tissue samples. In addition, we identify two coding variants in SPATA20 and UQCC1 that are associated with arm fat mass. SPATA20K422R is a low-frequency variant with a large effect on arm fat only, and UQCC1R51Q is a common variant reaching significance for arm but showing similar trends in other subcutaneous fat depots. Our findings support the notion that different fat compartments are regulated by distinct genetic factors.
- 30 May 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0217644
Open AccessRegional fat depot masses are influenced by protein-coding gene variants
Waist-to-hip ratio (WHR) is a prominent cardiometabolic risk factor that increases cardio-metabolic disease risk independently of BMI and for which multiple genetic loci have been identified. However, WHR is a relatively crude proxy for fat distribution and it does not capture all variation in fat distribution. We here present a study of the role of coding genetic variants on fat mass in 6 distinct regions of the body, based on dual-energy X-ray absorptiometry imaging on more than 17k participants. We find that the missense variant CCDC92S70C, previously associated with WHR, is associated specifically increased leg fat mass and reduced visceral but not subcutaneous central fat. The minor allele-carrying transcript of CCDC92 is constitutively more highly expressed in adipose tissue samples. In addition, we identify two coding variants in SPATA20 and UQCC1 that are associated with arm fat mass. SPATA20K422R is a low-frequency variant with a large effect on arm fat only, and UQCC1R51Q is a common variant reaching significance for arm but showing similar trends in other subcutaneous fat depots. Our findings support the notion that different fat compartments are regulated by distinct genetic factors.